Cargando…

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis

The study aimed to assess the risk of myocardial infarction (MI) and major adverse cardiac events during non-vitamin K antagonist oral anticoagulants (NOAC) compared to warfarin therapy in patients with atrial fibrillation (AF), both treated and not treated with percutaneous coronary interventions (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grajek, Stefan, Kałużna-Oleksy, Marta, Siller-Matula, Jolanta M., Grajek, Maksymilian, Michalak, Michał
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539187/ https://www.ncbi.nlm.nih.gov/pubmed/34683155 http://dx.doi.org/10.3390/jpm11101013

Ejemplares similares

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
por: Eyileten, Ceren, et al.
Publicado: (2020)

Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention
por: Koziński, Marek, et al.
Publicado: (2020)

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
por: Noseworthy, Peter A., et al.
Publicado: (2022)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Peri-Procedural Troponin Elevation after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease
por: Skorupski, Wojciech Jan, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

A Personalized Approach to Percutaneous Coronary Interventions in the Left Main Coronary Artery—Is the Female Gender Associated with Worse Outcomes?
por: Kałużna-Oleksy, Marta, et al.
Publicado: (2021)

Use of Anticoagulant Therapy in Patients with Acute Myocardial Infarction and Atrial Fibrillation
por: Lasica, Ratko, et al.
Publicado: (2022)

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
por: Schnabel, Renate B, et al.
Publicado: (2023)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Small buddy balloon catheter technique facilitates deliverability of other balloons or stents in challenging cases
por: Iwanczyk, Sylwia, et al.
Publicado: (2021)

Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants
por: Goette, Andreas, et al.
Publicado: (2020)

Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
por: Kwon, Soonil, et al.
Publicado: (2021)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report
por: Schnaubelt, Sebastian, et al.
Publicado: (2020)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
por: Saliba, Walid
Publicado: (2015)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
por: Caturano, Alfredo, et al.
Publicado: (2019)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Medication adherence and its determinants in patients after myocardial infarction
por: Pietrzykowski, Łukasz, et al.
Publicado: (2020)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
por: Friberg, Leif, et al.
Publicado: (2017)

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer
por: Kim, Kyu, et al.
Publicado: (2018)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures
por: Steffel, Jan
Publicado: (2020)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
Publicado: (2020)

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2019)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Significance of antiplatelet therapy in emergency myocardial infarction treatment
por: Komosa, Anna, et al.
Publicado: (2014)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

The impact of ischemia-reperfusion injury on the effectiveness of primary angioplasty in ST-segment elevation myocardial infarction
por: Araszkiewicz, Aleksander, et al.
Publicado: (2013)

Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction
por: Jortveit, Jarle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_079575ja6vbdndskig1ifh9mq9